Ibandronate: An IV injection for the treatment for postmenopausal osteoporosis

Bone

Volumn 41, Issue 5 SUPPL. 1, 2007, Pages

  Rizzoli, René ^a   Reid, David M ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Bisphosphonate; Bone mineral density; Fracture; Ibandronate; Postmenopausal osteoporosis

Indexed keywords

IBANDRONIC ACID; PLACEBO; VITAMIN D;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; KIDNEY DISEASE; POSTMENOPAUSE OSTEOPOROSIS;

EID: 35348821360     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.08.006     Document Type: Article

References (20)

1. Reginster J.Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
3. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
4. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
5. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
6. Barrett J., Worth E., Bauss F., and Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44 (2004) 951-965
7. Neugebauer G., Hagena C., Sakalova A., Kaufmann B., and Endele R. Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma. Eur J Clin Pharmacol 54 (1998) A18
8. Thiebaud D., Burckhardt P., Kriegbaum H., Huss H., Mulder H., Juttmann J.R., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103 (1997) 298-307
9. Recker R.R., Stakkestad J., Chesnut C., Christiansen C., Skag A., Høiseth A., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
10. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11 (1996) 1531-1538
11. Adami S., Felsenberg D., Christiansen C., Robinson J., Lorenc R.S., Mahoney P., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
12. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
13. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
14. Delmas P.D., Recker R.R., Chesnut III C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
15. Delmas P.D., Adami S., Strugala C., Stakkestad J., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA Study. Arthritis Rheum 54 (2006) 1838-1846
16. Papapoulos S.E., and Schimmer R.C. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66 (2007) 853-858
17. Bounameaux H.M., Schifferli J., Montani J.P., Jung A., and Chatelanat A. Renal failure associated with intravenous diphosphonates. Lancet 1 (1983) 471
18. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J.A., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7 (2001) 377-387
19. Markowitz G.S., Fine P.L., Stack J.I., Kunis C.L., Radhakrishnan J., Palecki W., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64 (2003) 281-289
20. Chang J.T., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349 (2003) 1676-1679